{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mannitol+%2820%25%29&page=2", "query": { "intervention": "Mannitol (20%)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mannitol+%2820%25%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mannitol+%2820%25%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T02:47:33.500Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00951743", "title": "Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Adaptavir (monomeric DAPTA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rapid Laboratories Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2009-07", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2009-08-11", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951743" }, { "nct_id": "NCT02861898", "title": "Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Brain Cancer", "Brain Neoplasm", "Brain Tumor", "Brain Neoplasm, Malignant", "EGFR Gene Overexpression", "GBM" ], "interventions": [ { "name": "Intra-arterial Cetuximab", "type": "DRUG" }, { "name": "Intra-arterial Mannitol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2016-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02861898" }, { "nct_id": "NCT06473779", "title": "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Asthma" ], "interventions": [ { "name": "Tezepelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Budesonide/formoterol", "type": "COMBINATION_PRODUCT" }, { "name": "Albuterol/budesonide (AIRSUPRA®)", "type": "COMBINATION_PRODUCT" }, { "name": "Mannitol", "type": "COMBINATION_PRODUCT" }, { "name": "Salbutamol", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 310, "start_date": "2024-09-30", "completion_date": "2027-06-25", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 8, "location_summary": "Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "Palmdale", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06473779" }, { "nct_id": "NCT00947882", "title": "A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lower Urinary Tract Symptoms (LUTS)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Degarelix 10 mg", "type": "DRUG" }, { "name": "Degarelix 20 mg", "type": "DRUG" }, { "name": "Degarelix 30 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "MALE", "summary": "50 Years and older · Male only" }, "enrollment_count": 404, "start_date": "2009-08", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 15, "location_summary": "Homewood, Alabama • Mobile, Alabama • Newport Beach, California + 12 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00947882" }, { "nct_id": "NCT03893045", "title": "A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Iron Deficiency Anemia" ], "interventions": [ { "name": "ferumoxytol", "type": "DRUG" }, { "name": "Iron sucrose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 75, "start_date": "2019-09-18", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Buford", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893045" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT01578785", "title": "An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-Remitting Multiple Sclerosis" ], "interventions": [ { "name": "Glatiramer Acetate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 178, "start_date": "2012-03", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 25, "location_summary": "Cullman, Alabama • Fresno, California • La Jolla, California + 17 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578785" }, { "nct_id": "NCT05428007", "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Ipilimumab Injection", "type": "DRUG" }, { "name": "Nivolumab/Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 105, "start_date": "2023-02-02", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428007" }, { "nct_id": "NCT03970447", "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Paxalisib", "type": "DRUG" }, { "name": "VAL-083", "type": "DRUG" }, { "name": "VT1021", "type": "DRUG" }, { "name": "Troriluzole", "type": "DRUG" }, { "name": "ADI-PEG 20", "type": "BIOLOGICAL" }, { "name": "AZD1390", "type": "DRUG" }, { "name": "Tinostamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Global Coalition for Adaptive Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2250, "start_date": "2019-07-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 42, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970447" }, { "nct_id": "NCT03619850", "title": "A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease; Iron Deficiency Anemia" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "Iron sucrose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 129, "start_date": "2018-08-13", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-10T02:47:33.500Z", "location_count": 8, "location_summary": "Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03619850" } ] }